Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000.Lancet. 2012; 379: 2151-2161
- Foodborne illness acquired in the United States–unspecified agents.Emerg Infect Dis. 2011; 17: 16-22
- Evaluation of the Luminex xTAG Gastrointestinal Pathogen Panel and the Savyon Diagnostics Gastrointestinal Infection Panel for the detection of enteric pathogens in clinical samples.J Med Microbiol. 2014; 63: 1419-1426
- Comparative evaluation of two commercial multiplex panels for detection of gastrointestinal pathogens by use of clinical stool specimens.J Clin Microbiol. 2014; 52: 3667-3673
- Multiplex molecular testing for management of infectious gastroenteritis in a hospital setting: a comparative diagnostic and clinical utility study.Clin Microbiol Infect. 2014; 20: O460-O467
- Added value of multiplex Luminex Gastrointestinal Pathogen Panel (xTAG® GPP) testing in the diagnosis of infectious gastroenteritis.Clin Microbiol Infect. 2014; 20: O182-O187
- Performance of the xTAG® gastrointestinal pathogen panel, a multiplex molecular assay for simultaneous detection of bacterial, viral, and parasitic causes of infectious gastroenteritis.J Microbiol Biotechnol. 2013; 23: 1041-1045
- Acute-phase proteins and other systemic responses to inflammation.N Engl J Med. 1999; 340: 448-454
- The occurrence during acute infections of a protein not normally present in the blood: I. Distribution of the reactive protein in patients' sera and the effect of calcium on the flocculation reaction with C polysaccharide of pneumococcus.J Exp Med. 1941; 73: 173-182
- C-reactive protein in viral and bacterial gastroenteritis in childhood.Acta Paediatr. 1996; 85: 670-674
- Lipopolysaccharide binding protein, interleukin-6 and C-reactive protein in acute gastrointestinal infections: value as biomarkers to reduce unnecessary antibiotic therapy.Infection. 2011; 39: 327-331
- Tumor necrosis factor-alpha and interleukin-10 in viral and bacterial gastroenteritis in children.J Chin Med Assoc. 2005; 68: 250-253
- The diagnostic value of serum interleukins 6 and 8 in children with acute gastroenteritis.J Pediatr Gastroenterol Nutr. 2006; 43: 25-29
- C-reactive protein levels for diagnosis of Salmonella gastroenteritis.Pediatr Infect Dis J. 1999; 18: 471-473
- Evaluation of faecal calprotectin as a valuable non-invasive marker in distinguishing gut pathogens in young children with acute gastroenteritis.Acta Paediatr. 2010; 99: 1389-1395
- Discriminatory potential of C-reactive protein, cytokines, and fecal markers in infectious gastroenteritis in adults.Diagn Microbiol Infect Dis. 2013; 77: 79-84
- Interferon-alpha in viral and bacterial gastroenteritis: a comparison with C-reactive protein and interleukin-6.Acta Paediatr. 1999; 88: 592-594
- Serum cytokines in differentiating between viral and bacterial enterocolitis.Ann Trop Paediatr. 2004; 24: 337-343
- Serum C-reactive protein (CRP) levels in young adults can be used to discriminate between inflammatory and non-inflammatory diarrhea.Dig Dis Sci. 2013; 58: 504-508
- Edmund Biernacki (1866–1911): discoverer of the erythrocyte sedimentation rate. On the 100th anniversary of his death.Clin Dermatol. 2011; 29: 697-703
- Diagnostic performance of serum interleukin-6 and interleukin-10 levels and clinical predictors in children with rotavirus and norovirus gastroenteritis.Cytokine. 2012; 59: 299-304
- Laboratory detection of sepsis: biomarkers and molecular approaches.Clin Lab Med. 2013; 33: 413-437
- IL-6 in inflammation, immunity, and disease.Cold Spring Harb Perspect Biol. 2014; 6: a016295
- The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk.J Lipid Res. 2007; 48: 751-762
- Role of scintigraphy in inflammatory bowel disease.World J Gastroenterol. 2009; 15: 2693-2700
- Fecal leukocytes in diarrheal illness.Ann Intern Med. 1972; 76: 697-703
- Prevalence and risk factors for asymptomatic Clostridium difficile carriage.Clin Infect Dis. 2014; 59: 216-222
- Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.Clin Microbiol Rev. 2013; 26: 604-630
- Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections.J Clin Microbiol. 2011; 49: 2887-2893
- Fecal leukocyte stain has diagnostic value for outpatients but not inpatients.J Clin Microbiol. 2001; 39: 266-269
- Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.World J Gastroenterol. 2014; 20: 363-375
- Measurement of fecal lactoferrin as a marker of fecal leukocytes.J Clin Microbiol. 1992; 30: 1238-1242
- Influence of lactoferrin on host-microbe interactions.in: Lactoferrin–-interactions and biological functions. vol. 28. Humana Press, Totowa (NJ)1997: 259-275
- Immunochemical detection of human lactoferrin in feces as a new marker for inflammatory gastrointestinal disorders and colon cancer.Clin Biochem. 1994; 27: 259-264
- The use of fecal calprotectin as a biomarker in gastrointestinal disease.Expert Rev Gastroenterol Hepatol. 2014; 8: 197-210
- Diagnostic accuracy of stool assays for inflammatory bacterial gastroenteritis in developed and resource-poor countries.Clin Infect Dis. 2003; 37: 365-375
- From guaiac to immune fecal occult blood tests: the emergence of technology in colorectal cancer screening.Gastroenterol Nurs. 2005; 28: 90-96
- Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease.Scand J Gastroenterol. 1999; 34: 50-54
- Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology.Aliment Pharmacol Ther. 2004; 20: 615-621
- High faecal calprotectin levels in healthy, exclusively breast-fed infants.Neonatology. 2010; 97: 299-304
- High faecal calprotectin concentrations in newborn infants.Arch Dis Child Fetal Neonatal Ed. 2004; 89: F353-F355
- Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children.Acta Paediatr. 2002; 91: 45-50
- Faecal calprotectin concentrations in apparently healthy children aged 0–12 years in urban Kampala, Uganda: a community-based survey.BMC Pediatr. 2011; 11: 9
- Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm.Am J Gastroenterol. 2001; 96: 2683-2687
- A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease.Aliment Pharmacol Ther. 2013; 37: 613-621
- Faecal markers of gastrointestinal inflammation.J Clin Pathol. 2012; 65: 981-985
- Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea.Am J Med. 2008; 121: 1099-1106
- Evaluation of fecal calprotectin in Campylobacter concisus and Campylobacter jejuni/coli gastroenteritis.Scand J Gastroenterol. 2013; 48: 633-635
- Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children.J Pediatr Gastroenterol Nutr. 2012; 55: 541-547
Article info
Publication history
Published online: March 19, 2015
Footnotes
Disclosures: M.D. Gonzalez and C.B. Wilen have no relevant financial relationships to disclose. C.A. Burnham has received research support from Cepheid, bioMerieux, and Accelerate Diagnostics.
Identification
Copyright
© 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
